Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma

Clinical Cancer Research

Volumn 22, Issue 14, 2016, Pages 3458-3466

  Satoh, Kei ^a,b   Zhang, Lisa ^a   Zhang, Yaqin ^c   Chelluri, Raju ^d   Boufraqech, Myriem ^a   Nilubol, Naris ^a   Patel, Dhaval ^a   Shen, Min ^c   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE; NERVE CELL ADHESION MOLECULE; NICLOSAMIDE; VIMENTIN; ANTINEOPLASTIC AGENT; CADHERIN;

ADRENAL CORTEX CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BD140A CELL LINE; CANCER INHIBITION; CARCINOMA CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; ENERGY METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; HIGH THROUGHPUT SCREENING; IC50; IN VIVO STUDY; MITOCHONDRION; MOUSE; NCIH295R CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SW 13 CELL LINE; WESTERN BLOTTING; ADRENAL CORTEX TUMOR; ANIMAL; CELL CYCLE CHECKPOINT; CELL CYCLE G1 PHASE; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CADHERINS; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MITOCHONDRIA; NICLOSAMIDE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976550425     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2256     Document Type: Article

References (40)

1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?World J Surg 2006;30:872-8.
2. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853-78.
3. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013;98:4551-64.
4. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37.
5. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28.
6. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-26.
7. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009;23:273-89.
8. The National Academies Press Drug Repurposing and Repositioning: Workshop summary. The National Academies Press: Washington DC; 2014.
9. Mehta A, Zhang L, Boufraqech M, Liu-Chittenden Y, Zhang Y, Patel D, et al. Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer. Clin Cancer Res 2015;21:4123-32.
10. Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther 1982;19:245-95.
11. Tao H, Zhang Y, Zeng X, Shulman GI, Jin S. Niclosamide ethanolamineinduced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med 2014;20:1263-9.
12. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, et al. The antihelminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009;48:10267-74.
13. Wieland A, Trageser D, Gogolok S, Reinartz R, Hofer H, Keller M, et al. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res 2013;19:4124-36.
14. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 2011;71:4172-82.
15. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010;70:2516-27.
16. You S, Li R, Park D, Xie M, Sica GL, Cao Y, et al. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther 2014;13:606-16.
17. Londono-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, et al. Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther 2014;13:800-11.
18. Arend RC, Londono-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, et al. Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol 2014;134:112-20.
19. Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 2015;75:1341-53.
20. King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, et al. WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene 2015;34:3452-62.
21. Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol 1987;113:101-22.
22. Durand J, Lampron A, Mazzuco TL, Chapman A, Bourdeau I. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. J Clin Endocrinol Metab 2011;96: E1206-11.
23. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014;46:607-12.
24. Kikuchi A, Yamamoto H, Kishida S. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 2007;19:659-71.
25. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, et al. betacatenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011;17:328-36.
26. Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefevre L, et al. Silencing mutated beta-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS One 2013;8: e55743.
27. Salomon A, Keramidas M, Maisin C, Thomas M. Loss of beta-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition. Oncotarget 2015;6:11421-33.
28. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
29. Warburg O, Posener K, Negelein E. On the metabolism of carcinoma cells. Biochemische Zeitschrift 1924;152:309-44.
30. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447-64.
31. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 2015;11:9-15.
32. Rosano C. Molecular model of hexokinase binding to the outer mitochondrial membrane porin (VDAC1): implication for the design of new cancer therapies. Mitochondrion 2011;11:513-9.
33. Gambert S, Ricquier D. Mitochondrial thermogenesis and obesity. Curr Opin Clin Nutr Metab Care 2007;10:664-70.
34. Han YH, Kim SW, Kim SH, Kim SZ, Park WH. 2,4-dinitrophenol induces G1 phase arrest and apoptosis in human pulmonary adenocarcinoma Calu-6 cells. Toxicol In Vitro 2008;22:659-70.
35. Pardo-Andreu GL, Nunez-Figueredo Y, Tudella VG, Cuesta-Rubio O, Rodrigues FP, Pestana CR, et al. The anti-cancer agent nemorosone is a new potent protonophoric mitochondrial uncoupler. Mitochondrion 2011;11:255-63.
36. Jara JA, Castro-Castillo V, Saavedra-Olavarria J, Peredo L, Pavanni M, Jana F, et al. Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice. J Med Chem 2014;57:2440-54.
37. Han YH, Moon HJ, You BR, Kim SZ, Kim SH, Park WH. Effects of carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone on the growth inhibition in human pulmonary adenocarcinoma Calu-6 cells. Toxicology 2009; 265:101-7.
38. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006;25:4812-30.
39. Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Mitochondrion 2004;4:755-62.
40. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-8.